The primary objective of this study is to evaluate the efficacy, safety, and tolerability of 4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in subjects who are between 18 and 70 years of age, inclusive
Study Type
INTERVENTIONAL
Purpose
TREATMENT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Birmingham, Alabama, United States
Unnamed facility
Huntsville, Alabama, United States
Unnamed facility
Mobile, Alabama, United States
Unnamed facility
Northport, Alabama, United States
Unnamed facility
Phoenix, Arizona, United States
Unnamed facility
Little Rock, Arkansas, United States
Unnamed facility
Irvine, California, United States
Unnamed facility
Northridge, California, United States
Unnamed facility
Sacramento, California, United States
Unnamed facility
Fort Collins, Colorado, United States
...and 51 more locations